Swiss dental technology firm vVardis—founded by dentist sisters Haley and Goly Abivardi—has filed for an initial public offering on the New York Stock Exchange (NYSE) under the ticker “VVVV”, highlighting rapid US expansion for its non-invasive cavity treatments.
📌 Key Financials & IPO Details:
• $28.6 Million Revenue: First-half 2026 revenue surged more than 3x from $9.1M in the same period last year. • $27.8 Million Net Loss: Narrowed from a $32.1M net loss in H1 2025 as commercial scaling accelerated.
• 20,000+ Dental Practices: vVardis products are now adopted by over 20,000 of the ~110,000 general dental offices across the US.
• Heavyweight Backers: Supported by premier healthcare investors, including OrbiMed, Heartland Dental, and affiliates of Apollo Global Management.
• Top Wall Street Underwriters: Led by Goldman Sachs, J.P. Morgan, William Blair, UBS Investment Bank, Deutsche Bank Securities, and Apollo Global Securities.
💡 Market Takeaway: While the broader US IPO market remains cautious and selective, healthcare and medtech firms continue to demonstrate resilience, leveraging strong fundamental growth to tap public capital markets.